Premium
Bioresorbable vascular scaffold implantation for severely calcified lesions after excimer laser lesion preparation
Author(s) -
Mitomo Satoru,
Jabbour Richard J.,
Latib Azeem,
Colombo Antonio
Publication year - 2018
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.27704
Subject(s) - medicine , lesion , excimer laser , excimer , bioresorbable scaffold , scaffold , radiology , laser , surgery , biomedical engineering , percutaneous coronary intervention , myocardial infarction , optics , physics
Abstract Bioresorbable vascular scaffolds (Absorb BVS, Abbott Vascular, Santa Clara, CA) temporarily elute antiproliferative drugs and provide vessel support, which then subsequently resorb to allow restoration of normal vessel function and architecture. To attain the best possible results with BVS, a dedicated implantation technique (PSP: adequate lesion preparation, proper sizing, postdilatation) is considered mandatory, and calcified lesions are one of the most challenging lesion subsets for BVS implantation. In five cases with severe calcifications refractory to balloon predilatation, we performed excimer laser catheter ablation (ELCA: Turbo Elite catheter; Spectranetics Corporation, Colorado Springs, CO, USA), which facilitated adequate lesion expansion with high‐pressure noncompliant balloon inflation and BVS implantation. During the follow‐up period (481 days [interquartile range: 445–579]), all patients continued dual antiplatelet therapy (DAPT) and there were no cases of cardiac death, myocardial infarction, or scaffold thrombosis. For treatment of severely calcified lesions with bioresorbable scaffolds, ELCA could be considered an effective potential strategy. After the procedure, prolonged DAPT was prescribed.